Abstract: The main pathologies of Alzheimer’s disease (AD) are the accumulation of amyloid-β (Aβ) and tau tangles, and these two fundamental pathologies accompany the various neuropathological features, such as neuroinflammation, loss of synapse and neurogenesis, disruption of the blood-brain barrier (BBB), autophagy dysfunction, and cognitive impairment (Lee et al., 2014; Sweeney et al., 2018; Kashyap et al., 2019; Park et al., 2022). AD is thus considered a multi-factorial disease in which each of these complex neuropathological features somehow interrelates, eventually leading to neuronal and functional loss in the nervous system. Although researchers have focused on Aβ and tau tangles for the development of therapeutics for AD, the clinical efficacy of drugs targeting these major pathologies remains controversial. Moreover, other currently available drugs that are not effective in treating AD solely provide symptomatic relief to patients with AD. For this reason, researchers are on the onlook for new strategies to treat AD and emphasize the importance of multi-target directed drugs.